This document discusses guidelines for managing hyperlipidemia in diabetic patients. Several studies analyzed showed that reducing lipid levels, especially LDL-C, statistically decreases cardiovascular events and mortality in high-risk populations like diabetics. The results of these studies led to developing and updating treatment guidelines for hyperlipidemia in diabetics. The guidelines aim to lower atherogenic cholesterol and reduce cardiovascular events. Clinical trials showed that therapies like ezetimibe, evolocumab, and alirocumab reduced LDL-C and major cardiovascular events. Diabetic patients benefited more than non-diabetic patients.
This document discusses guidelines for managing hyperlipidemia in diabetic patients. Several studies analyzed showed that reducing lipid levels, especially LDL-C, statistically decreases cardiovascular events and mortality in high-risk populations like diabetics. The results of these studies led to developing and updating treatment guidelines for hyperlipidemia in diabetics. The guidelines aim to lower atherogenic cholesterol and reduce cardiovascular events. Clinical trials showed that therapies like ezetimibe, evolocumab, and alirocumab reduced LDL-C and major cardiovascular events. Diabetic patients benefited more than non-diabetic patients.
This document discusses guidelines for managing hyperlipidemia in diabetic patients. Several studies analyzed showed that reducing lipid levels, especially LDL-C, statistically decreases cardiovascular events and mortality in high-risk populations like diabetics. The results of these studies led to developing and updating treatment guidelines for hyperlipidemia in diabetics. The guidelines aim to lower atherogenic cholesterol and reduce cardiovascular events. Clinical trials showed that therapies like ezetimibe, evolocumab, and alirocumab reduced LDL-C and major cardiovascular events. Diabetic patients benefited more than non-diabetic patients.
MANAGEMENT OF HYPERLIPIDEMIA IN THE DIABETIC PATIENT
In an article published in the printed version of the Journal of Medicine and Public Health (MSP), several randomized controlled studies were analyzed that showed that the reduction of lipid levels, specifically low-density lipoprotein or LDL-C, statistically decreases the events and cardiovascular mortality in populations with high risk of these, especially diabetics. According to the article, “the most conclusive information is with the use of HMGCoA reductase inhibitors or statins. These have shown that, in patients with documented or higher risk atherosclerotic disease such as diabetics, they are of cardiovascular benefit, regardless of the level of LDL-C base (high, low or normal). The results of these studies led to the development and updating of therapeutic guidelines for the management of hyperlipidemias in diabetics. Dyslipidemia treatment The purpose of these guidelines is to decrease the level of atherogenic cholesterol and reduce cardiovascular events, with the aim of establishing correspondence between professionals and patients, which is emphasized in the latest update of these guidelines. The guidelines have been aimed at recommending a certain statin dose intensity, depending on the patient's risk, maintaining the use of numerical parameters previously called goals, given the results of recent studies that show patients with already documented cardiovascular atherosclerotic disease. treated with statin therapy at maximum tolerated doses and, who have not obtained an optimal LDL-C or nonHDL-C level (<70 mg / dL and <100 mg / dL respectively. The therapies used in these clinical trials are the intestinal cholesterol absorption inhibitor, ezetimibe and the PCSK9 enzyme inhibitors. A study called IMPROVE IT with ezetimibe showed a 7% reduction in cardiovascular events using ezetimibe, added to moderate intensity statin therapy (simvastatin 20 mg). For their part, the FOURIER and ODYSSEY OUTCOMES studies, with evolocumab and alirocumab, respectively, showed that these PCSK9 inhibitors decreased LDL-C to more than 50% and, in turn, obtained a 15% reduction in major cardiovascular events. In all three studies, diabetic patients showed superior benefit compared to non-diabetics. ESPAÑOL TRADUCIDO EN EL TRADUCTOR DEEPL MANEJO DE HIPERLIPIDEMIA EN EL PACIENTE DIABÉTICO En un artículo publicado en la versión impresa de la Revista Medicina y Salud Pública (MSP) se analizaron varios estudios aleatorios controlados que demostraron que la reducción de niveles de lípidos, concretamente la lipoproteína de densidad baja o LDL-C, disminuye estadísticamente los eventos y mortalidad cardiovascular en las poblaciones con alto riesgo de estos, en especial los diabéticos. Según el artículo “la información más contundente es con el uso de inhibidores de reductasa HMGCoA o estatinas. Estas han evidenciado que, en pacientes con enfermedad aterosclerótica documentada o de mayor riesgo como los diabéticos, son de beneficio cardiovascular, independientemente del nivel de LDL-C de base (alto, bajo o normal)”. Los resultados de estos estudios llevaron al desarrollo y actualización de guías terapéuticas para el manejo de las hiperlipidemias en diabéticos. El tratamiento de dislipidemia El propósito de estas guías es disminuir el nivel de colesterol aterogénico y reducir los eventos cardiovasculares, con el objetivo de que exista correspondencia entre profesionales y pacientes se enfatiza en la última actualización de dichas guías. Las guías se han encaminado a recomendar cierta intensidad de dosis de estatina, dependiendo del riesgo del paciente, manteniendo el uso de parámetros numéricos antes llamados metas, esto dados los resultados de los estudios recientes en los que se muestran pacientes con enfermedad aterosclerótica cardiovascular documentada ya tratados con terapia de estatina a dosis máximas toleradas y, que no han obtenido un nivel de LDL-C o nonHDL-C óptimo ( < 70 mg/dL y < 100 mg/dL respectivamente. Las terapias utilizadas en estos ensayos clínicos son el inhibidor de absorción intestinal de colesterol, ezetimibe y los inhibidores de la enzima PCSK9. Un estudio llamado IMPROVE IT con ezetimibe demostró una reducción del 7% en eventos cardiovasculares usando ezetimibe, añadido a terapia con estatina de intensidad moderada (simvastatina 20 mg). Por su parte los estudios FOURIER y ODYSSEY OUTCOMES, con evolocumab y alirocumab respectivamente, demostraron que dichos inhibidores de PCSK9 disminuyen a más del 50% el LDL-C y, a su vez, obtuvieron un 15% de reducción en eventos mayores cardiovasculares. En los tres estudios los pacientes diabéticos mostraron un beneficio superior comparado a los no diabéticos.
INGLES TRADUCIDO EN LA APLICACIÓN DE DEEPL
MANAGEMENT OF HYPERLIPIDEMIA IN THE DIABETIC PATIENT In an article published in the printed version of the Journal of Medicine and Public Health (MSP), several randomized controlled studies were analyzed that showed that the reduction of lipid levels, specifically low density lipoprotein or LDL-C, statistically decreases cardiovascular events and mortality in populations at high risk of these, especially diabetics. According to the article "the most compelling information is with the use of HMGCoA reductase inhibitors or statins. These have shown that, in patients with documented atherosclerotic disease or those at higher risk such as diabetics, they are of cardiovascular benefit, regardless of the baseline LDL-C level (high, low or normal)". The results of these studies led to the development and updating of therapeutic guidelines for the management of hyperlipidemias in diabetics. The treatment of dyslipidemia The purpose of these guidelines is to lower the level of atherogenic cholesterol and reduce cardiovascular events, with the objective of correspondence between professionals and patients being emphasized in the latest update of these guidelines. The guidelines have aimed to recommend a certain intensity of statin doses, depending on the patient's risk, maintaining the use of numerical parameters previously called goals, this given the results of recent studies showing patients with documented atherosclerotic cardiovascular disease already treated with statin therapy at maximum tolerated doses and, which have not obtained an optimal LDL-C or nonHDL-C level ( < 70 mg/dL and < 100 mg/dL respectively. The therapies used in these clinical trials are cholesterol intestinal absorption inhibitor, ezetimibe and PCSK9 enzyme inhibitors. A study called IMPROVE IT with ezetimibe showed a 7% reduction in cardiovascular events using ezetimibe, added to moderate intensity statin therapy (simvastatin 20 mg). The FOURIER and ODYSSEY OUTCOMES studies, with evolocumab and alirocumab respectively, showed that these PCSK9 inhibitors reduced LDL-C by more than 50% and, in turn, obtained a 15% reduction in major cardiovascular events. In all three studies diabetic patients showed a superior benefit compared to non-diabetic patients. COMPARACIÓN Bueno la comparación de la traducción podremos decir que tiene ventaja, pero también desventaja. Es decir que nos pueden ayudar a entender textos, pero no a traducirlos como una persona. Bueno observe que, si es casi similar al original, pero hay algunas palabras que son traducido a su manera del traductor. Bueno mencionare las desventajas y desventajas del traductor DEEPL en internet. Una de las ventajas que puedo mencionar es de la aplicación del traductor en el internet en línea. Como: Ahorro considerable de tiempo al tener que evitar buscar una palabra o más en el diccionario del idioma correspondiente. Obtención de correcciones ortográficas y gramaticales al instante, proporcionando también ayuda en el aprendizaje y la práctica de esos mismos aspectos. Generalmente, se tiene una gran variedad de idiomas y dialectos disponibles en una misma herramienta, lo que nos permite realizar si lo deseamos, más de una traducción en un corto período de tiempo. El fácil acceso a través de cualquier dispositivo digital o computadora. Su utilización no cuenta con ningún tipo de costo Y la desventaja seria: La traducción nunca es perfecta, aunque generalmente se acerca a un 90% de precisión en la mayoría de los traductores. Al pasar de un lenguaje a otro, las incongruencias gramaticales pueden hacerse presentes en un idioma que no es el original. La traducción literal de expresiones que se usan de manera coloquial o figurativa, resultando en frases un tanto absurdas en un lenguaje que no es el nativo.